AU2018215673B2 - Compositions and methods for augmenting antibody mediated receptor signaling - Google Patents

Compositions and methods for augmenting antibody mediated receptor signaling Download PDF

Info

Publication number
AU2018215673B2
AU2018215673B2 AU2018215673A AU2018215673A AU2018215673B2 AU 2018215673 B2 AU2018215673 B2 AU 2018215673B2 AU 2018215673 A AU2018215673 A AU 2018215673A AU 2018215673 A AU2018215673 A AU 2018215673A AU 2018215673 B2 AU2018215673 B2 AU 2018215673B2
Authority
AU
Australia
Prior art keywords
antibody
amino acid
polypeptide
region
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018215673A
Other languages
English (en)
Other versions
AU2018215673A1 (en
Inventor
Wayne A. Marasco
Quan Karen ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2018215673A1 publication Critical patent/AU2018215673A1/en
Application granted granted Critical
Publication of AU2018215673B2 publication Critical patent/AU2018215673B2/en
Priority to AU2025202811A priority Critical patent/AU2025202811A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018215673A 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling Active AU2018215673B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202811A AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202811A Division AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Publications (2)

Publication Number Publication Date
AU2018215673A1 AU2018215673A1 (en) 2019-07-25
AU2018215673B2 true AU2018215673B2 (en) 2025-01-23

Family

ID=63040120

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018215673A Active AU2018215673B2 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling
AU2025202811A Pending AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202811A Pending AU2025202811A1 (en) 2017-02-06 2025-04-22 Compositions and methods for augmenting antibody mediated receptor signaling

Country Status (7)

Country Link
US (2) US20220213206A1 (OSRAM)
EP (1) EP3576793A4 (OSRAM)
JP (3) JP7231549B2 (OSRAM)
CN (1) CN110520158A (OSRAM)
AU (2) AU2018215673B2 (OSRAM)
CA (1) CA3049689A1 (OSRAM)
WO (1) WO2018145075A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102534568B1 (ko) * 2016-07-22 2023-05-18 다나-파버 캔서 인스티튜트 인크. 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN120309734A (zh) 2021-01-13 2025-07-15 威特拉公司 人源化补体5a受体1抗体和其使用方法
US20240239905A1 (en) * 2021-05-13 2024-07-18 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
AU2023324667A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150353636A1 (en) * 2013-01-10 2015-12-10 Genmab B.V. Human igg1 fc region variants and uses thereof
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) * 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
WO2018083126A1 (en) * 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
US9963513B2 (en) * 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
DK3189081T3 (da) * 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
EP3215528B1 (en) * 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
CN110214152B (zh) * 2016-10-14 2025-06-13 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150353636A1 (en) * 2013-01-10 2015-12-10 Genmab B.V. Human igg1 fc region variants and uses thereof
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) * 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
WO2018083126A1 (en) * 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DI ZHANG ET AL: "Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 53, 30 December 2016 (2016-12-30), pages 27134 - 27146 *

Also Published As

Publication number Publication date
EP3576793A4 (en) 2021-03-31
AU2025202811A9 (en) 2026-03-05
CN110520158A (zh) 2019-11-29
EP3576793A1 (en) 2019-12-11
US20220213206A1 (en) 2022-07-07
JP7231549B2 (ja) 2023-03-01
JP2023036899A (ja) 2023-03-14
AU2025202811A1 (en) 2025-05-08
CA3049689A1 (en) 2018-08-09
JP7606501B2 (ja) 2024-12-25
JP2020505054A (ja) 2020-02-20
JP2025028191A (ja) 2025-02-28
AU2018215673A1 (en) 2019-07-25
US20240336694A1 (en) 2024-10-10
WO2018145075A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
US20250066481A1 (en) Fc variant compositions and methods of use thereof
US20220056131A1 (en) CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3
JP7397882B2 (ja) 二重特異性抗体及びその調製方法、使用
CN118440201A (zh) 靶向肿瘤的激动性cd28抗原结合分子
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
RU2819624C2 (ru) Композиции анти-cd112r антител и сопутствующие способы
US20240132593A1 (en) Anti-vista antibodies and uses thereof
CN120322455A (zh) 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)